Capital Performance Advisors LLP Actinium Pharmaceuticals, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 437 shares of ATNM stock, worth $629. This represents 0.0% of its overall portfolio holdings.
Number of Shares
437Holding current value
$629% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ATNM
# of Institutions
74Shares Held
8.31MCall Options Held
65.2KPut Options Held
21.7K-
Black Rock Inc. New York, NY1.88MShares$2.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$2.34 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA686KShares$988,0600.0% of portfolio
-
State Street Corp Boston, MA603KShares$867,8140.0% of portfolio
-
Acadian Asset Management LLC Boston, MA454KShares$653,3190.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $36.3M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...